---
title: Characterization and root cause analysis of immunogenicity to pasotuxizumab
  (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager
  therapy
date: '2023-11-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37942314/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231109170834&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'INTRODUCTION: In oncology, anti-drug antibody (ADA) development that
  significantly curtails response durability has not historically risen to a level
  of concern. The relevance and attention ascribed to ADAs in oncology clinical studies
  have therefore been limited, and the extant literature on this subject scarce. In
  recent years, T cell engagers have gained preeminence within the prolific field
  of cancer immunotherapy. These drugs whose mode of action is expected to potently
  stimulate ...'
disable_comments: true
---
INTRODUCTION: In oncology, anti-drug antibody (ADA) development that significantly curtails response durability has not historically risen to a level of concern. The relevance and attention ascribed to ADAs in oncology clinical studies have therefore been limited, and the extant literature on this subject scarce. In recent years, T cell engagers have gained preeminence within the prolific field of cancer immunotherapy. These drugs whose mode of action is expected to potently stimulate ...